Literature DB >> 1476655

Pharmacology of agents used in bone marrow transplant conditioning regimens.

V J Wiebe1, B R Smith, M W DeGregorio, J M Rappeport.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1476655     DOI： 10.1016/1040-8428(92)90092-5

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  12 in total

Review 1.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

2.  Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience.

Authors:  Daniel C Moreira; Margaret E Macy; Carrye R Cost; Brian S Greffe; Timothy P Garrington
Journal:  J Pediatr Hematol Oncol       Date:  2019-03       Impact factor: 1.289

Review 3.  High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.

Authors:  Christopher J Campen; Rebecca L Tombleson; Myke R Green
Journal:  J Neurooncol       Date:  2010-07-04       Impact factor: 4.130

4.  Nosocomial epiglottitis associated with penicillin- and cephalosporin-resistant Streptococcus pneumoniae bacteremia.

Authors:  R S Daum; J P Nachman; C D Leitch; F C Tenover
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

5.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

6.  Inducible disruption of the c-myb gene allows allogeneic bone marrow transplantation without irradiation.

Authors:  C Stremmel; R Schuchert; V Schneider; T Weinberger; R Thaler; D Messerer; S Helmer; F Geissmann; J Frampton; S Massberg; C Schulz
Journal:  J Immunol Methods       Date:  2018-04-06       Impact factor: 2.303

7.  Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Authors:  Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 31.777

8.  Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Authors:  Behnam Sadeghi; Suleiman Al-Hashmi; Zuzana Hassan; Bjorn Rozell; Hernan Concha; Carin Lundmark; Kjell-Olov Grönvik; Manuchehr Abedi-Valugerdi; Moustapha Hassan
Journal:  Clin Dev Immunol       Date:  2010-12-21

9.  Current and emerging pharmacotherapies for primary CNS lymphoma.

Authors:  Prathima Prodduturi; Philip J Bierman
Journal:  Clin Med Insights Oncol       Date:  2012-05-21

10.  Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient.

Authors:  Vincent Camus; Sydney Dubois; Stéphane Lepretre; Fabrice Jardin; Hervé Tilly
Journal:  Clin Case Rep       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.